Lipocine Phase 3 trial of LPCN 1154 in postpartum depression misses primary endpoint

 

 post hoc analysis shows benefit signals

• Lipocine is evaluating next steps for LPCN 1154 in postpartum depression after the failed Phase 3.
• The company plans to seek FDA breakthrough therapy and fast track designations for LPCN 1154.

https://finviz.com/quote.ashx?t=LPCN&p=d